Sepragen.com

Home | Contact Us 


Online Catalog


View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at sales@sepragen.com.



How Can We Help You?
Click here to contact us!

 



Sepragen Corporation Establishes Internet Presence

HAYWARD, CA, September 15, 1998 – Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) announced today its latest effort in providing better support and services to its customers by establishing Internet presence.

Sepragen develops and sells processes and products using its proprietary technology for the dairy, citrus juice and biopharmaceutical markets. Although no commercial agreements have been reached yet, it has previously announced evaluation of these processes by several international companies that are leaders in their respective fields. Sepragen also continues to sell equipment and instrumentation to biotechnology companies for use in scale-up and manufacturing of pharmaceuticals. The company currently holds twelve US patents and seven foreign patents relating to its technologies. As of September 30,1997, Sepragen has 2,155,254 Class A common shares, 701,177 Class B super voting common shares, each convertible into one share of Class A common and 1,203,719 Class E common shares convertible into Class B shares, but which vest only if the Company meets certain substantial earnings thresholds or stock price targets before December 31, 1999.

Return to News Archives main page



The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.


Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2018 Sepragen Corporation. All rights reserved. (510) 475-0650